Clinical trial
An Open-Label Exploratory Phase 2/3 Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer
NCT03414983 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Exploratory Phase 2/3 Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- February 20, 2018
- Completion date
- December 28, 2022
- Enrollment
- 196 (actual)
- Sites
- 49
Conditions
As the registry lists them; a condition with its own page is linked.
colorectal cancer